Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, semaglutide can help reduce A1C levels in people with type 2 diabetes. Clinical trials have demonstrated average A1C reductions ranging from 1.5% to 2.0%, with some patients achieving greater improvements depending on baseline glucose control, lifestyle factors, and medication adherence.

Understanding your individual metabolic profile—including baseline A1C, insulin resistance patterns, and genetic predispositions in glucose regulation pathways—can support more targeted conversations with your provider about whether semaglutide fits your health goals. PlexusDx emphasizes precision-guided medication selection rather than assuming one approach works for everyone.

How Semaglutide Affects Blood Sugar Control

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone regulating blood sugar. It slows gastric emptying, increases insulin secretion in response to meals, and decreases glucagon release—collectively lowering postprandial and fasting glucose levels.

The medication's effect on A1C reflects average blood sugar over approximately three months. Studies show that semaglutide's glucose-lowering capacity is dose-dependent, with higher doses generally producing larger A1C reductions in responsive patients. Individual variation in response is significant and warrants provider monitoring.

Clinical Evidence: A1C Reduction Across Dose Ranges

Multiple phase 3 trials have documented semaglutide's A1C-lowering efficacy. The following table summarizes typical reductions observed at common therapeutic doses in people with inadequate baseline glycemic control.

Semaglutide Dose Baseline A1C (avg) A1C Reduction (avg) Study Duration
0.5 mg weekly 8.2% 1.0–1.2% 30 weeks
1.0 mg weekly 8.4% 1.4–1.6% 30 weeks
2.0 mg weekly 8.3% 1.8–2.0% 30 weeks
Combined lifestyle Varies +0.5–1.0% Ongoing management

Individual Variation: Why Some Patients Respond Differently

Not all patients experience identical A1C reductions at the same dose. Factors including baseline insulin secretion capacity, duration of diabetes, prior medication exposure, and genetic variation in GLP-1 receptor expression influence individual response magnitude and timeliness.

Patients with preserved beta-cell function and shorter disease duration often show larger A1C improvements. Those with long-standing diabetes or advanced beta-cell dysfunction may experience more modest reductions, though still clinically meaningful. Provider assessment of these factors informs realistic goal-setting.

Safety, Eligibility, and When Semaglutide May Not Be Appropriate

Semaglutide is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe renal impairment, or severe gastrointestinal disease. Pregnancy is a contraindication. Common side effects include nausea, vomiting, and diarrhea, which often diminish over time with dose titration.

Your healthcare provider should conduct a comprehensive metabolic assessment, review medication interactions, and establish baseline kidney and thyroid function before initiating semaglutide. Regular monitoring of A1C, weight, and gastrointestinal tolerance supports ongoing safety and efficacy evaluation.

How PlexusDx Supports a More Personalized Approach

Genetic variation in the GLP-1 receptor (GLP1R rs6923761) and other glucose-regulation pathways may help provide context for understanding why some patients respond robustly to semaglutide while others show more modest A1C reductions. PlexusDx's Precision Peptide Genetic Test evaluates predispositions in key peptide signaling variants, which can support a more informed conversation with your provider about medication selection.

The genetic test reveals predispositions in GLP1R, GIPR, FTO, and MC4R variants—markers that reflect underlying metabolic pathway function rather than guaranteeing exact medication response. These insights should be interpreted with a qualified healthcare provider as one data point among many, including clinical history, current medications, and metabolic biomarkers like fasting glucose and insulin levels.

Understanding your genetic predispositions alongside traditional biomarkers empowers a more personalized discussion with your provider about whether compounded or brand semaglutide aligns with your metabolic profile and treatment goals. This precision-guided approach may help optimize therapy selection and monitoring strategies.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How quickly does semaglutide lower A1C?

A1C changes reflect three-month average blood sugar, so meaningful reductions typically appear at eight to twelve weeks of consistent therapy. Maximum effect at a given dose usually manifests by week twenty to thirty, though individual timelines vary based on dose escalation and adherence.

Can semaglutide alone achieve normal A1C levels without other diabetes medications?

Semaglutide can reduce A1C significantly, but many patients require combination therapy with metformin or other agents to reach target levels. Your provider determines the appropriate regimen based on baseline A1C, kidney function, and individual glucose dynamics.

What is the cost of compounded semaglutide through PlexusDx?

PlexusDx offers compounded semaglutide injection from licensed 503A pharmacies at $149 monthly, or oral semaglutide starting at $209 monthly. Pricing depends on dose and delivery method. Consult with a PlexusDx provider to determine which formulation suits your clinical needs.

What happens to A1C if I stop taking semaglutide?

A1C typically rises after discontinuation, returning toward baseline over several weeks to months as blood sugar control reverts to prior levels. This underscores the importance of sustained therapy and lifestyle modifications to maintain glycemic benefits long-term.

Does the Precision Peptide Genetic Test predict whether semaglutide will work for me?

The test reveals predispositions in GLP1R and related glucose-regulation pathways, which may provide context for your metabolic phenotype. However, genetics alone do not predict exact medication response. Results should inform a provider discussion alongside clinical history and biomarkers for personalized medication planning.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves